诺贝尔奖得主屠呦呦 呼吁关注抗疟疾问题（中英双语）
青岛希尼尔翻译咨询有限公司（www.sinosenior.com）整理发布 2015-12-07
青岛希尼尔翻译公司（www.sinosenior.com）2015年12月7日了解到：“社会急需共同努力来抗击疟疾问题”，赢得2015年生理学或医学诺贝尔奖的屠呦呦说道。"Joint
efforts are urgently needed to combat malaria", China’s Tu Youyou who
won 2015 Nobel Prize in Physiology or Medicine said on Sunday.
Tu, sitting together with the other two laureates William C. Campbell
and Satoshi Omura, made such an appeal during Sunday’s press conference
for the Medicine Laureates at the Nobel Forum, Karolinska Institutet.
在卡罗林斯卡学院，屠呦呦和另外两个诺贝尔医学奖的获得者William C. Campbell 和 Satoshi Omura
一起出席新闻发布会时，发出了这样的呼吁。
"Malaria is a pandemic that can go easily out of control, especially
in low income regions such as Africa. So all parties should, under the
framework of the WHO(World Health Organization), try their best to delay
the process of Artemisinin resistance. "
“疟疾是一种很容易失控的流行病，尤其是在非洲这样的低收入地区。因此，各方应该在世界卫生组织的框架下一起努力来延缓青蒿素药性。”
"It’s hard to develop a new drug in the next decade, during which it
would be too late, if malaria became widespread." She said, adding that
she was "deeply worried about this possible outcome".
“在未来10年里研发出一种新药是很困难的，如果疟疾继续蔓延下去，一切都会晚了。”屠呦呦说道，“为可能产生的严重后果感到非常担心。”
Talking about the Traditional Chinese Medicine(TCM) where she found
the source and inspiration in successfully developing anti-malaria drug,
she emphasized on the value of TCM with "thousands of years’ history and
empirical knowledge" as "great treasure", and said "combining with
modern scientific technologies, more potential can be discovered in
searching for new drugs".
成功开发抗疟疾药物来源于中药所给的启示，强调了中药作为“千年历史和经验知识”是“大宝藏”，并说“结合现代科学技术，在寻找新药物方面更具潜力”。
Tu won 2015 Nobel Prize in Physiology or Medicine in early October for
her discoveries concerning a novel therapy against Malaria, artemisinin.
屠呦呦因为开发了抗击疟疾的药物青蒿素，因而在今年10月获得了诺贝尔医学奖。
Tu is scheduled to receive her award at the Nobel Prize Award Ceremony
on Thursday, and later attend the Nobel Banquet and Royal Banquet.
周四，屠呦呦在诺贝尔奖颁奖仪式上将领取奖杯，之后会出席诺贝尔盛宴和皇家级盛宴。 来源:环球时报
注：部分新闻来源于网路，如有涉及版权，请及时通知我们，我们将尽快删除。
---------------------------------------------------------------------------------------------------------------------------------------------------------------